Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 4/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.57 |
| ▸ | OXTR | P30559 | 3/20 | 0.50 |
| ▸ | PSMB11 | A5LHX3 | 1/20 | 0.43 |
| ▸ | PSMA7 | O14818 | 1/20 | 0.43 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.43 |
| ▸ | PSMA1 | P25786 | 1/20 | 0.43 |
| ▸ | PSMA2 | P25787 | 1/20 | 0.43 |
| ▸ | PSMA3 | P25788 | 1/20 | 0.43 |
| ▸ | PSMA4 | P25789 | 1/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.43 |
| ▸ | PSMA5 | P28066 | 1/20 | 0.43 |
| ▸ | PSMB4 | P28070 | 1/20 | 0.43 |
| ▸ | PSMB6 | P28072 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29465925 | 0.94 | HDAC3 (0.57) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL29465932 | 0.94 | HDAC3 (0.57) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL29390244 | 0.92 | SLC6A3 (0.52) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL29865959 | 0.92 | SLC6A3 (0.52) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| Bacillomycin D(C14) SCHEMBL29777427 | 0.85 | SLC6A3 (0.52) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| Bacillomycin D(C15) SCHEMBL29777429 | 0.85 | PLG (0.52) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL31612918 | 0.81 | KRAS (0.51) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL29884632 | 0.81 | KRAS (0.51) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL29390178 | 0.81 | PLG (0.51) | HDAC3HDAC1HDAC2HDAC10HDAC11 | |
| SCHEMBL29773723 | 0.80 | KRAS (0.49) | HDAC3HDAC1HDAC2HDAC10HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3755357-B1 | AN ANTIBIOTIC COMPOSITION COMPRISING MICELLES | SPOREGEN LTD (GB) | 2025-09-17 | — | — | EP | claimed |
| US-12171734-B2 | Pathogenic bacteria | SPOREGEN LIMITED (GB) | 2024-12-24 | — | — | US | claimed |
| US-20250295748-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | SPOREGEN LIMITED (GB) | 2025-09-25 | — | — | US | disclosed |
| EP-3755357-B1 | AN ANTIBIOTIC COMPOSITION COMPRISING MICELLES | SPOREGEN LTD (GB) | 2025-09-17 | — | — | EP | disclosed |
| US-12171734-B2 | Pathogenic bacteria | SPOREGEN LIMITED (GB) | 2024-12-24 | — | — | US | disclosed |
| EP-4208181-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | SporeGen Limited (GB) | 2023-07-12 | — | — | EP | disclosed |
| US-20220280579-A1 | Formulations for Prevention or Reduction of C. Difficile Infections | SPOREGEN LIMITED (GB) | 2022-09-08 | — | — | US | disclosed |
| EP-4017265-A1 | FORMULATIONS FOR PREVENTION OR REDUCTION OF C. DIFFICILE INFECTIONS | SporeGen Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| WO-2022049381-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | SPOREGEN LIMITED (GB) | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220280579-A1 | Formulations for Prevention or Reduction of C. Difficile Infections | SI, FABP2, CRY1 | HDAC3 397/4885HDAC1 2088/4885HDAC2 1095/4885 |
| US-12171734-B2 | Pathogenic bacteria | CLPP, CLPX, ANTXR2 | HDAC3 300/4885HDAC1 619/4885HDAC2 1324/4885 |
| US-20250295748-A1 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS | TLR3, TLR5, IRF3 | HDAC3 3184/4885HDAC1 3626/4885HDAC2 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.